Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 247

Results For "NDA"

4491 News Found

Zydus receives final approval from the USFDA for Oxcarbazepine Tablets
Drug Approval | July 05, 2023

Zydus receives final approval from the USFDA for Oxcarbazepine Tablets

The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)


CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
News | July 05, 2023

CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals

The 'A+' rating reflects IOL's robust business model, diversified product portfolio


Cipla bags sustainable companies rankings for 2022-23
News | July 05, 2023

Cipla bags sustainable companies rankings for 2022-23

Cipla has a robust governance model focused on sustainability


Evonik showcases smart technology for dental prostheses
News | July 05, 2023

Evonik showcases smart technology for dental prostheses

PEEK brings a new quality to dental care for patients


Venus Remedies gets marketing approvals for oncology medicine from 4 key markets
News | July 05, 2023

Venus Remedies gets marketing approvals for oncology medicine from 4 key markets

With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503


Merck India appoints Pratima Reddy as Country Speaker
People | July 05, 2023

Merck India appoints Pratima Reddy as Country Speaker

Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India


Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
News | July 04, 2023

Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules

The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models


Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24
Drug Approval | July 03, 2023

Alembic Pharmaceuticals receives USFDA approvals for 5 products in Q1FY24

Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.


Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
News | July 03, 2023

Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030

Intent to start at least 5 innovative Phase 3 vaccine programs by 2025


AstraZeneca announces US$400 million investment in reforestation and biodiversity
News | June 28, 2023

AstraZeneca announces US$400 million investment in reforestation and biodiversity

New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia